JP2015180703A5 - - Google Patents

Download PDF

Info

Publication number
JP2015180703A5
JP2015180703A5 JP2015141004A JP2015141004A JP2015180703A5 JP 2015180703 A5 JP2015180703 A5 JP 2015180703A5 JP 2015141004 A JP2015141004 A JP 2015141004A JP 2015141004 A JP2015141004 A JP 2015141004A JP 2015180703 A5 JP2015180703 A5 JP 2015180703A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cyano
chloro
insulin resistance
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015141004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015180703A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015180703A publication Critical patent/JP2015180703A/ja
Publication of JP2015180703A5 publication Critical patent/JP2015180703A5/ja
Ceased legal-status Critical Current

Links

JP2015141004A 2006-01-18 2015-07-15 Ppar調節因子 Ceased JP2015180703A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76024106P 2006-01-18 2006-01-18
US60/760,241 2006-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012286467A Division JP2013060465A (ja) 2006-01-18 2012-12-28 Ppar調節因子

Publications (2)

Publication Number Publication Date
JP2015180703A JP2015180703A (ja) 2015-10-15
JP2015180703A5 true JP2015180703A5 (enExample) 2016-03-17

Family

ID=38779054

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008550880A Pending JP2009523781A (ja) 2006-01-18 2007-01-18 Ppar調節因子
JP2012286467A Withdrawn JP2013060465A (ja) 2006-01-18 2012-12-28 Ppar調節因子
JP2015141004A Ceased JP2015180703A (ja) 2006-01-18 2015-07-15 Ppar調節因子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008550880A Pending JP2009523781A (ja) 2006-01-18 2007-01-18 Ppar調節因子
JP2012286467A Withdrawn JP2013060465A (ja) 2006-01-18 2012-12-28 Ppar調節因子

Country Status (13)

Country Link
US (2) US20110178112A1 (enExample)
EP (2) EP1976509B1 (enExample)
JP (3) JP2009523781A (enExample)
CN (3) CN101646344A (enExample)
AU (1) AU2007266714B2 (enExample)
CA (1) CA2637803A1 (enExample)
DK (1) DK1976509T3 (enExample)
ES (1) ES2533652T3 (enExample)
IN (1) IN2015DN00502A (enExample)
MX (1) MX2008009241A (enExample)
PL (1) PL1976509T3 (enExample)
RU (1) RU2449999C2 (enExample)
WO (1) WO2007138485A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007669A (es) * 2007-01-18 2011-12-08 Evolva Sa 1,3,-dioxanos sustituidos y sus usos.
AU2008206050B2 (en) * 2007-01-18 2014-08-14 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011057262A2 (en) * 2009-11-09 2011-05-12 Evolva Inc. Treatment of infections with tp receptor antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
EP2951287B1 (en) * 2013-02-04 2019-04-03 ETH Zurich Designer circuit controlling diet-induced obesity
CN106687506A (zh) 2014-07-03 2017-05-17 莫门蒂夫性能材料股份有限公司 酯官能的聚硅氧烷和由其制成的共聚物
US12485102B2 (en) 2017-08-02 2025-12-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
RU2674987C1 (ru) * 2018-04-17 2018-12-14 Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" АО "ВНЦ БАВ" 2-Аминия-7-(диэтиламино)-4-(4-метоксибензо[d][1,3]диоксол-5-ил)-4Н-хромен-3-карбонитрила N-ацетиламиноэтаноат, проявляющий противоопухолевую активность
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
EP4000615B1 (en) 2020-11-13 2022-10-19 Serodus ASA Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
GB8330120D0 (en) * 1983-11-11 1983-12-21 Ici Plc Chemical process
GB8511890D0 (en) * 1985-05-10 1985-06-19 Ici Plc Benzene derivatives
ES8802508A1 (es) * 1985-05-10 1988-07-16 Ici Plc Procedimiento para preparar derivados alquenicos.
GB8626297D0 (en) 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8901201D0 (en) * 1988-02-16 1989-03-15 Ici Plc Pyridine derivatives
US5248780A (en) * 1988-02-16 1993-09-28 Imperial Chemical Industries, Plc Pyridyl substituted alkenoic acid derivatives
IE81170B1 (en) * 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
US5128359A (en) * 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
WO1996041013A1 (en) 1995-06-07 1996-12-19 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6436997B1 (en) * 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2000030683A1 (en) * 1998-11-19 2000-06-02 Shionogi & C0., Ltd. Preventives and/or remedies for central nervous system diseases containing compounds having txa2 receptor antagonism and/or txa2 synthase inhibitory effect
US6291496B1 (en) 1999-12-27 2001-09-18 Andrew J. Dannenberg Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
US6284790B1 (en) * 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
US8071654B2 (en) * 2000-11-09 2011-12-06 Pace-Asciak Cecil R Inhibitors of thromboxane formation and action
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EP1267171A1 (en) 2001-06-14 2002-12-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cofactor-based screening method for nuclear receptor modulators
AU2003299648A1 (en) * 2002-12-12 2004-06-30 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-(1,3)-dioxanes
WO2004060282A2 (en) * 2002-12-19 2004-07-22 Synaptic Pharmaceutical Corporation Uses of the snorf207 receptor

Similar Documents

Publication Publication Date Title
JP2015180703A5 (enExample)
JP2012530705A5 (enExample)
JP2015508749A5 (enExample)
JP2013537203A5 (enExample)
JP2015145426A5 (enExample)
JP2016531126A5 (enExample)
JP2018533593A5 (enExample)
JP2012507535A5 (enExample)
JP2016506935A5 (enExample)
JP2016518328A5 (enExample)
JP2017517512A5 (enExample)
JP2018048154A5 (enExample)
JP2017530959A5 (enExample)
JP2016512505A5 (enExample)
JP2009523781A5 (enExample)
JP2015530389A5 (enExample)
JP2016006118A5 (enExample)
JP2010520306A5 (enExample)
JP2017537066A5 (enExample)
JP2013543896A5 (enExample)
JP2012255026A5 (enExample)
JP2016501250A5 (enExample)
JP2011513410A5 (enExample)
JP2020532545A5 (enExample)
JP2016528273A5 (enExample)